$CGTX SEC Filings

Filed On	Filing
22 Oct 2026	8-K: Other Events Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies
07 Aug 2026	10-Q
06 Aug 2026	8-K: Results of Operations and Financial Condition
24 Jun 2026	8-K: Other Events
22 Jun 2026	Form 4: Khattar Jack A., Director Received 25,000 shares as a grant or award
22 Jun 2026	Form 4: Monia Brett P, Director Received 25,000 shares as a grant or award
22 Jun 2026	Form 4: Wallace Peggy, Director Received 25,000 shares as a grant or award
22 Jun 2026	Form 4: Richstone Ellen B, Director Received 25,000 shares as a grant or award
22 Jun 2026	Form 4: Fletcher Aaron G.l., Director and 9 others Received 25,000 shares as a grant or award
18 Jun 2026	8-K: Submission of Matters to a Vote of Security Holders
04 Jun 2026	8-K: Regulation FD Disclosure
21 May 2026	8-K: Other Events
08 May 2026	10-Q
07 May 2026	8-K: Results of Operations and Financial Condition
04 May 2026	Form 4: Doyle John Brendan, Chief Financial Officer Gave up 8,567 shares to cover exercise price or tax ($11K)
27 Apr 2026	ARS
27 Apr 2026	DEFA14A
27 Apr 2026	Proxy statement: annual meeting on June 17, 2026
20 Apr 2026	Form 4: Doyle John Brendan, Chief Financial Officer Bought 10,000 shares ($11.3K)
20 Apr 2026	Form 4: Ricciardi Lisa, Director Bought 9,175 shares ($10.1K)

Comments